http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Fang Taishi ),( Hong Suk Kyun ),( Lee Kwang-woong ),( Yoon Kyung Chul ),( Kim Hyo-sin ),( Nugroho Adianto ),( Murokawa Takahiro ),( Kim Hyeyoung ),( Yi Nam-joon ),( Suh Kyung-suk ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Mycophenolate mofetil is the most common auxiliary immunosuppressant after liver transplantation to relieve calcineurin inhibitor related complications. There is one type of Cellcept<sup>®</sup> available, but Myrept<sup>®</sup> produced by Chong Kun Dang Company in Korea is available as 500 mg tablet as well as 250 mg capsule. However, there has been no clinical study to assess the feasibility of this generic product. Therefore, we aimed to evaluate the feasibility, cost-effectiveness, and convenience of Myrept<sup>®</sup> 500 mg tablet in recipients after liver transplantation. Methods: A 24 week, phase 4, single center, open-label, non-comparative study was employed. A total of 50 patients were recruited. Acute rejection, changes in blood chemistry, white blood cell count, renal function, adverse drug reaction and other characteristics of the patients were recorded for 24 weeks Results: All enrolled patients and their grafts were survived within 24 weeks. Mean GFR was 119.61 ± 76.52 ml/min at beginning of the study and reached 85.20 ± 23.70 ml/min after 24 weeks and showed a significant decrease overall (p < 0.001).Nine patients (18.75%) had adverse drug reactions which had been commonly reported in other Mycophenolate mofetil generic products, and there was no serious one. These adverse reactions included gastrointestinal problems (nausea, vomiting, and abdominal discomfort), laboratory abnormality (mild increase of aspartate or alanine aminotransferase). The size of Myrept<sup>®</sup> 500 mg tablet is smaller than Myrept<sup>®</sup> 250 mg capsule (17.1 x 7.1 x 6.5 mm vs. 19.18 x 7.23 x 6.40 mm). When comparing the same dose, the cost is less expensive (1,344 Korean won vs. 1,792 Korean won for 500 mg). Conclusions: In conclusion, Myrept<sup>®</sup> 500 mg tablet is feasible, cost-effective, and convenient in recipients after liver transplantation.